Effect of Teriparatide on Intertrochanteric Fractures Healing
Phase 3
- Conditions
- Intertrochanteric Fractures.
- Registration Number
- IRCT20201121049452N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
People over 50 years old with intertrochanteric fractures
use Triaparatide for a period of 3 months after surgery
Vitamin D with normal serum levels
Exclusion Criteria
Teriparatide is prescribed before surgery
Teriparatide is prescribed for less than 3 months
Unacceptable fracture reduction
Multiple fractures
Underlying conditions, or self-medication that affects bone repai
Contralateral pelvic fractures
Pathological fractures
Any anti-osteoporosis medication (except calcium and vitamin d tablets)
Deficiencies in medical records
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fracture healing time. Timepoint: Imaging at 2 and 4 weeks after surgery, then every 4 weeks until the fracture heals after taking teriparatide. Method of measurement: Radiological evaluation.
- Secondary Outcome Measures
Name Time Method